Search for: clinical-trials-as-topic
Early detection of immunization: A study based on an animal model using 1H nuclear magnetic resonance spectroscopy, Article Pakistan Journal of Biological Sciences ; Volume 14, Issue 3 , 2011 , Pages 195-203 ; 10288880 (ISSN) ; Arjmand, M ; Tafazzoli, M ; Ghohzadeh, A ; Pourfallah, F ; Sadeghi, S ; Mirzazadeh, R ; Mirkham, F ; Tahen, S ; Iravam, A ; Bayat, P ; Vahabi, F ; Sharif University of Technology
Vaccines require a period of at least three months for clinical trials, hence a method that can identify elicitation of immune response a few days after the first dose is a necessity. Evolutionary variable selections are modeling approaches for proper manipulation of available data which were used to set up an animal model for classification of time dependent 'HNMR metabolomic profiles and pattern recognition of fluctuations of metabolites in two groups of male rabbits. One group of rabbits was immunized with human red blood cells and the other used as control. Blood was obtained every 48 h from each rabbit for a period of six weeks and the serum monitored for antibodies and metabolites by...
Article Nanomedicine ; Volume 11, Issue 5 , 2016 , Pages 513-530 ; 17435889 (ISSN) ; Zare, H ; Bakhshian Nik, A ; Yazdani, N ; Hamrang, M ; Mohamed, E ; Sahandi Zangabad, P ; Moosavi Basri, S. M ; Bakhtiari, L ; Hamblin, M. R ; Sharif University of Technology
Future Medicine Ltd
Nanotechnology could provide a new complementary approach to treat coronary artery disease (CAD) which is now one of the biggest killers in the Western world. The course of events, which leads to atherosclerosis and CAD, involves many biological factors and cellular disease processes which may be mitigated by therapeutic methods enhanced by nanotechnology. Nanoparticles can provide a variety of delivery systems for cargoes such as drugs and genes that can address many problems within the arteries. In order to improve the performance of current stents, nanotechnology provides different nanomaterial coatings, in addition to controlled-release nanocarriers, to prevent in-stent restenosis....
Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes, Article AAPS Journal ; Volume 19, Issue 3 , 2017 , Pages 652-668 ; 15507416 (ISSN) ; Fathe, K. R ; Brunaugh, A ; Ferrati, S ; Li, S ; Montenegro Nicolini, M ; Mousavikhamene, Z ; McConville, J. T ; Prausnitz, M. R ; Smyth, H. D. C ; Sharif University of Technology
Springer New York LLC 2017
Biologic products are large molecules such as proteins, peptides, nucleic acids, etc., which have already produced many new drugs for clinical use in the last decades. Due to the inherent challenges faced by biologics after oral administration (e.g., acidic stomach pH, digestive enzymes, and limited permeation through the gastrointestinal tract), several alternative routes of administration have been investigated to enable sufficient drug absorption into systemic circulation. This review describes the buccal, sublingual, pulmonary, and transdermal routes of administration for biologics with relevant details of the respective barriers. While all these routes avoid transit through the...
The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?, Article Microbial Pathogenesis ; Volume 148 , November , 2020 ; Miri, S. M ; Abdolalipour, E ; Ghaemi, A ; Sharif University of Technology
Academic Press 2020
Respiratory virus infections are among the most prevalent diseases in humans and contribute to morbidity and mortality in all age groups. Moreover, since they can evolve fast and cross the species barrier, some of these viruses, such as influenza A and coronaviruses, have sometimes caused epidemics or pandemics and were associated with more serious clinical diseases and even mortality. The recently identified Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a Public Health Emergency of International concern and has been associated with rapidly progressive pneumonia. To ensure protection against emerging respiratory tract...
Article Cancer Cell International ; Volume 20, Issue 1 , September , 2020 ; Tafsiri, E ; Cho, W. C. S ; Ghaemi, A ; Sharif University of Technology
BioMed Central Ltd 2020
Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients, a so called "adoptive cell transfer", or ACT, process. Construction of allogeneic T-cells is dependent on the employment of a gene-editing tool to modify donor-extracted T-cells and prepare them to specifically act against tumor cells with enhanced function and durability and least side-effects. In this context, CRISPR technology can be used to produce universal T-cells, equipped with recombinant T cell...